Vericel Corp Ord
$ 35.14
2.03%
14 Apr - close price
- Market Cap 1,754,084,000 USD
- Current Price $ 35.14
- High / Low $ 35.42 / 34.42
- Stock P/E 107.62
- Book Value 7.01
- EPS 0.32
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.05 %
- 52 Week High 45.97
- 52 Week Low 28.95
About
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$55.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-07-31 | 2025-05-06 | 2025-02-26 | 2024-11-07 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-02 | 2023-05-10 |
| Reported EPS | 0.45 | 0.1 | -0.01 | -0.23 | 0.38 | -0.02 | -0.1 | -0.08 | 0.26 | -0.08 | -0.11 | -0.16 |
| Estimated EPS | 0.3938 | -0.01 | -0.03 | -0.1533 | 0.34 | -0.05 | -0.08 | -0.11 | 0.17 | -0.12 | -0.15 | -0.15 |
| Surprise | 0.0562 | 0.11 | 0.02 | -0.0767 | 0.04 | 0.03 | -0.02 | 0.03 | 0.09 | 0.04 | 0.04 | -0.01 |
| Surprise Percentage | 14.2712% | 1100% | 66.6667% | -50.0326% | 11.7647% | 60% | -25% | 27.2727% | 52.9412% | 33.3333% | 26.6667% | -6.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCEL
2026-04-15 13:40:11
Truist has lowered its price target for Vericel (VCEL) to $42 from $48, while maintaining a Buy rating on the stock. This adjustment comes despite recent positive news for Vericel, including a significant BARDA contract and FDA approval for a new manufacturing facility. The company specializes in advanced therapies for sports medicine and severe burn care, with products like MACI, Epicel, and NexoBrid.
2026-04-15 11:40:11
Vericel Corporation (VCEL) has received FDA approval for the commercial manufacturing of its MACI product. This approval signifies a significant regulatory milestone for the company, indicating that its manufacturing processes meet the required standards for bringing MACI to market. This development could potentially enhance Vericel's ability to meet product demand and expand its market presence.
2026-04-14 13:39:25
The Critical Limb Ischemia (CLI) market was valued at approximately USD 1,845 million in 2023 and is projected to grow significantly by 2034, driven by increasing prevalence and a rich pipeline of emerging therapies. The United States held the largest market share in 2023, while Germany led the European market. Key companies like Boston Scientific, Ixaka, and Hemostemix are developing new treatments, including drug-coated balloons and cell therapies, to address this severe peripheral artery disease.
2026-04-10 11:09:00
Vericel Corp (VCEL) reported record third-quarter 2025 revenue of $67.5 million, exceeding guidance, with GAAP net income over $5 million and an adjusted EBITDA margin of 25%. This strong performance was driven by a 25% increase in Macy revenue, including the successful launch of Macy Arthro. The company also generated record operating cash flow and plans to initiate a phase 3 Macy ankle clinical study, despite acknowledging uncertainties for 2026 guidance and potential variability in burn care revenue and increased operating expenses.
2026-04-06 20:11:08
Vericel's Chief Medical Officer, Jonathan Mark Hopper, exercised stock options for 3,472 shares at $10.95 and subsequently sold those shares at $35.00 on April 2, 2026, under a pre-planned 10b5-1 trading plan. After these transactions, Hopper directly holds 75,556 common shares and 9,132 exercisable stock options. The original option grant for 135,000 shares had a vesting schedule and an expiration date of August 20, 2028.
2026-04-06 07:10:23
Aberdeen Group plc increased its stake in Vericel Corporation (NASDAQ:VCEL) by 7.6% in the fourth quarter, now holding 583,884 shares valued at $21.03 million. Other institutional investors also adjusted their positions in the biotechnology company. Vericel reported strong quarterly earnings with $0.45 EPS, meeting estimates, and revenue up 23.3% year-over-year, while analysts maintain a "Moderate Buy" rating with an average price target of $56.00.
